Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies
详细信息 查看全文
- 作者：Romain Guiè ; ze1 ; Gandhi Damaj2 ; Bruno Pereira3 ; Marie Robin4 ; Patrice Chevallier5 ; Mauricette Michallet6 ; Sté ; phane Vigouroux7 ; Yves Beguin8 ; Didier Blaise9 ; Jean El Cheikh9 ; Damien Roos-Weil10 ; Anne Thiebaut11 ; Pierre-Simon Rohrlich12 ; Anne Huynh13 ; Jé ; rô ; me Cornillon14 ; Nathalie Contentin15 ; Felipe Suarez16 ; Bruno Lioure17 ; Mohamad Mohty18 ; Natacha Maillard19 ; Laurence Clement20 ; Sylvie Franç ; ois21 ; Gaë ; lle Guillerm22 ; Ibrahim Yakoub-Agha23 ; ibrahim.yakoubagha@live.fr" class="auth_mail" title="E-mail the corresponding author
- 关键词：Myelodysplastic syndrome ; Allogeneic hematopoietic stem cell transplantation ; Relapse ; Prognosis ; Donor lymphocyte infusion
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：22
- 期：2
- 页码：240-247
- 全文大小：797 K
文摘
- •
Myelodysplastic syndromes relapsing after allogeneic hematopoietic stem-cell transplantation are associated with poor 2-year OS that is significantly and independently influenced by history of acute graft-versus-host disease, relapse within 6 months after allo-SCT, progression to AML and platelet count < 50 g/L at relapse.
- •
Immunotherapy (second allo-SCT or donor lymphocyte infusion) is the therapeutic of choice whenever possible.